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Abstract
BACKGROUND: Accurate staging is important for management decisions in patients with newly diagnosed breast cancer. 
AIM: This study was conducted to evaluate the value of 18 fluorine-fluorodeoxyglucose (18F-FDG) positron emission 
tomography/computed tomography (PET/CT) imaging in breast cancer staging..
METHODS: A prospective study of 80 patients (1 male and 79 female) mean age 51.13 years with histologically 
confirmed breast cancer. The staging procedures included history, physical examination, mammography, and CT of 
neck, chest, abdomen, and pelvis; then, PET/CT was performed in a time interval <30 days. The findings of PET/CT 
were compared with those of the other conventional methods.
RESULTS: The agreement between conventional methods (mammography, breast ultrasound, contrast-enhanced 
CT of the neck, chest, abdomen, and pelvis) and 18F FDG-PET/CT was 0.6 for assessing the T stage, 0.39 for N 
stage, and 0.75 for M stage. There was moderate agreement between CT and 18F FDG-PET/CT in the detection of 
nodal lesions (K=0.6) and pulmonary lesions (K=0.51), while a perfect agreement was noted for detecting osseous 
(K=0.82) and liver lesions (K=0.81). In total, 50 patients (62.5%) were concordantly staged between the conventional 
imaging and 18F-FDG PET/CT, while 30 patients (37.5%) showed a different tumor, node, and metastasis stage. 
The changes were driven by the detection of additional findings (n=26) or exclusion of findings (n=4), mainly at the 
lymph nodes (LNs) and/or distant sites. Regarding N status, 18F FDG-PET/CT revealed previously unknown regional 
lymphatic spread in supraclavicular (n=4; 5%), infraclavicular (n=11; 13.7%), and internal mammary (n=12; 15%) 
lymph node groups. 18F-FDG PET/CT changed M status in a total of four patients (5%); three of them were upstaged 
by detecting distant metastases, while osseous deposits were excluded in one patient leading to downstaging.
CONCLUSION: 18F-FDG-PET/CT is considered a valuable imaging tool in the initial staging of breast cancer, which 
significantly impacts the overall American Joint Committee on Cancer staging in 37.5% of our study population.
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Background
Breast cancer remains the most commonly 
diagnosed cancer in women. It is the main cause 
of death from cancer in women in the world and 
affecting not only the elderly but also younger 
patients [1]. Accurate staging is important for deciding 
on therapy and defining the prognosis. 18 fluorine-
fluorodeoxyglucose (18F-FDG) positron emission 
tomography/computed tomography (PET/CT) has the 
advantage of providing both functional and anatomic 
information compared with only the anatomic 
description provided by conventional imaging. 
18F-FDG-PET has an important role in diagnostic 
staging, recurrence evaluation, and assessment the 
response to therapy [2].18F-FDG PET/CT fusion studies 
have the advantage of anatomic characterization in 
addition to the functional information provided by PET. 
Furthermore, it would be less likely to mistake the 
normal physiologic accumulation seen in some PET 
studies when no corresponding lesion is observed 
on the CT portion. An important advantage of 18F-
FDG PET/CT is its ability to depict malignant disease 
in lymph nodes that do not appear pathologically 
enlarged at CT and in the evaluation of regional 
lymph nodes, in particular, is its greater accuracy 
for detecting and locating metastases in the internal 
mammary and supraclavicular lymph nodes [3], [4]. 
PET is more efficient than CT or bone scintigraphy 
for depicting lytic or mixed bone metastases and 
bone marrow lesions. 18F-FDG PET could be more 
sensitive in detecting lytic metastases than sclerotic 
metastases; the latter lesions commonly show low-
grade uptake and less commonly appear completely 
devoid of any FDG activity [5]. Nonetheless, they 
show osteo-condensation on underlying CT images 
so that they can be efficiently detected by hybrid PET/
CT [6]. Many studies have shown that 18F-FDG PET/
CT is more accurate than the conventional methods 
in staging breast carcinoma, accordingly impacted the 
therapeutic management of the patients [6].
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In this study, we aimed to evaluate the value of 
18F-FDG PET/CT in detecting distant lesions in patients 
with breast cancer who were assessed by conventional 
imaging methods and its impact in staging and changing 
therapeutic management.
Methods
The Institutional Review Board approved this 
prospective study. During the period from November 
2017 to September 2019, 80 eligible patients were 
included in this study (1 male and 79 female; mean 
age 51±13 years). The common eligibility criteria were 
a histopathologically confirmed diagnosis of breast 
cancer and pretherapy (staging) whole-body 18F-FDG 
PET/CT study performed with contrast-enhanced 
CT (CE-CT). All the PET/CT studies were performed 
either at the Center of Clinical Oncology and Nuclear 
medicine (NEMROCK). However, other parts of 
the conventional work-up (mammography, breast 
ultrasound, and/or bone scans) were performed in 
outside institutions.
We excluded pregnant ladies and patients who 
had surgical excision of the tumor, previously received 
chemo or radiotherapy.
All patients underwent clinical assessment 
by an oncologist experienced in breast cancer 
management. The evaluation procedures included 
history, physical examination, mammography with/
without breast ultrasound, and CE-CT of neck, chest, 
abdomen, and pelvis. Mammography and breast 
ultrasound were performed in many outside institutions, 
according to their intuitional protocols. Whole-body 
CE-CT was part of the 18F-FDG PET/CT acquisition.
18F-FDG PET/CT acquisition and 
reconstruction protocol
Patients were instructed for preparation 
according to the EANM procedure guidelines for 
18F-FDG PET/CT tumor imaging: Version 2.0 [7]. Briefly, 
patients were required to fast for 6 h and asked to void 
before the examination. The patients were instructed 
to stay calm and avoid walking or any exercise before 
and after injection of 18F-FDG to prevent physiologic 
muscle FDG uptake. Blood glucose level measured 
before injection and fasting levels were <200 mg/dL 
(70–170 mg/dL in our cohort). Warm environment was 
available before injection to avoid brown fat uptake.
A dose of 3.7–5.2 MBq/Kg of 18F-FDG was 
injected through a hand or antecubital vein, contralateral 
to the breast lesion, or using foot veins in the presence 
of bilateral breast lesions. The injection was performed 
45–90 min before the start of PET/CT acquisition. For 
opacification of bowel loops, 400-600 ml of contrast 
material diluted with water and swallowed 1 h before 
PET/CT imaging.
The scanner used in NEMROCK was Ingenuity 
TF 64 (Philips Healthcare, Cleveland, OH, USA), a 
PET/CT scanner combining a modular, LYSO-based 
PET component with a 64-channel CT component. The 
CT was based on the Ingenuity CT (Philips Healthcare).
Acquisition and reconstruction protocol was 
previously described [8]. Briefly, a low-dose non-
contrast CT scan was performed first followed by a 
whole-body PET acquisition then a whole-body CE-CT 
scan.
Low-dose CT was acquired in a helical mode, 
using 120 kV, 60 mAs, and a 512 × 512 matrix size, 
acquiring a field of view (FOV) of 700 mm. This CT scan 
was used for attenuation correction.
PET scan was acquired in a three-dimensional 
mode over the same anatomical regions starting 
from the skull vertex to the level of the mid-thigh. The 
acquisition time was 2 min per bed position, in 9-bed 
positions. Reconstructed slice thickness was 5 mm.
Immediately after completing PET acquisition, 
a diagnostic CT with contrast was acquired using 
120 kV, 300 mAs, and a 512 × 512 matrix size. The 
acquired FOV was 500 mm using dose automatic 
modulation in the Z direction. Non-ionic contrast media 
were IV injected using automatic injector at a rate of 
4 ml/s, in a dose of 1–2 ml/kg (maximum <150 ml). Slice 
thickness was 1.0 mm.
The whole study took about 20–30 min. 
Raw data were reconstructed using a standard 
manufacturer’s iterative algorithm. Axial PET and CT 
images obtained and then reformatted into sagittal and 
coronal images to allow easier image interpretation.
PET/CT and CE-CT interpretation
Two nuclear medicine physicians with 7 and 13 
years of experience, read the 18F-FDG PET/CT study, 
together with the CE-CT images, but blinded to the 
radiological readings. CE-CT was independently and 
blindly read by an experienced radiologist (16-years’ 
experience). A checklist for local tumor extension 
(T status), regional lymph node involvement (N status), 
and distant lesions (M status) was used for both 
modalities. The three components (T, N, and M) were 
collectively used to stage the patient according to the 
American Joint Committee on Cancer (AJCC) staging 
system, 8th Edition.
On 18F-FDG PET/CT, lesions were considered 
positive if 18F-FDG uptake was focally increased in the 
lesion and was greater than surrounding background 
tissues. Any discrepancy between the two readers was 
solved by consensus.
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Evaluation of the impact
Initial clinical staging was performed by 
the oncologist, according to conventional work-up, 
including the CE-CT reads, then, the treatment plans 
were decided using only this information. The results of 
18F FDG-PET/CT were then revealed and any changes 
in the individual component of the T, N, and/or M states 
were recorded and a new treatment plan was discussed. 
Any change in management based on the new 18F-FDG 
PET/CT findings was recorded.
Statistical analysis
Data were statistically described in terms of 
mean ± standard deviation (SD), median and range, 
or frequencies (number of cases) and percentages 
as appropriate. Correlation was performed using 
Spearman rank correlation for ordinal and continuous 
variables with non-normal distributions. McNemar’s 
test was used to measure the difference in proportions 
of disagreement between the two modalities (18F-FDG 
PET/CT and conventional work-up). Kappa coefficient 
used to measure the agreement between the two 
modalities. The level of agreement was categorized 
as poor (k < 0), slight (k = 0–0.20), fair (k = 0.21–0.4), 
moderate (k = 0.41–0.6), substantial (k = 0.61–0.8), and 
perfect agreement (k = 0.81–1.0) [9]. All analyses were 
performed using SPSS version 21 (IBM Corp, Armonk, 
NY, USA).
Results
Of the 80 patients recruited in this study, 50 
(62.5%) were interpreted on 18F-FDG PET/CT as 
having the same tumor, node, and metastasis (TNM) 
stage that was reported on conventional imaging, 
while 30 patients (37.5%) had their AJCC stage 
changed according to the findings from 18F-FDG PET/
CT. In the majority of them (26/30; 32.5% of the total 
study cohort), 18F-FDG PET/CT detected new lesions, 
previously unseen by conventional imaging, leading 
to upstaging. On the other hand, the remaining four 
patients (5%) were downstaged based on impressions 
from FDG PET/CT. There was a moderate agreement 
between conventional methods and 18F FDG-PET/CT in 
final TNM staging (K = 0.60).
Details of the TNM individual components are 
summarized in Table 1.
In 54 patients (67.5%), both methods showed 
the same T status, while 26 patients (32.5%) showed 
different local findings. 18F-FDG PET/CT detected 
multifocal lesions (i.e., in different quadrants) more 
frequently (n = 19, 23.7%) compared to the combination 
of mammography and ultrasonography (n = 8, 10%). 
Furthermore, 18F-FDG PET/CT detected multicentric 
lesions (i.e., within the same quadrant) in 10 patients 
(12.5%) compared to four patients (5%) detected by 
conventional methods.
Table 1: TNM staging
TNM Conventional (n %) PET/CT (n %) Value of Kappa
T1N0M0 1 (1.3) 0 (0) 0.60
T0N1M0 0 (0) 0 (0)
T1N1M0 3 (3.8) 0 (0)
T2N0M0 1 (1.3) 1 (1.3)
T2N1M0 6 (7.5) 2 (2.5)
T3N0M0 1 (1.3) 1 (1.3)
T3N1M0 8 (10) 10 (12.5)
T0N2M0 0 (0) 0 (0)
T1N2M0 1 (1.3) 0 (0)
T2N2M0 2 (2.5) 2 (2.5)
T3N2M0 1 (0) 4 (5)
T4N0M0 1 (1.3) 2 (2.5)
T4N1M0 6 (7.5) 2 (2.5)
T4N2M0 5 (6.3) 3 (3.8)
Any T N3M0 5 (6.3) 11 (13.8)
Any T&N M1 39 (48.8) 42 (52.5)
TNM: Tumor, node, and metastasis.
18F-FDG PET/CT changed nodal status (N) in 
35 patients (43.7%), mostly by upstaging (n=28, 35%) 
and less frequently by downstaging (n = 7, 8.7%). 
18F-FDG PET/CT revealed previously undetectable 
loco-regional lymphatic spread in infraclavicular 
(n = 11; 13.7%), supraclavicular (n = 4; 5%), and internal 
mammary (n = 12; 15%) nodal groups.
18F-FDG PET/CT changed the distant status 
(M) in four patients (5%) and three patients (3.7%) 
were upstaged by detecting distant lesions (2 distant 
LN lesions and 1 bone lesion). While in one patient, 18F 
FDG-PET/CT excluded osseous deposits.
Figure 1: Three dimensional maximum intensity projection (a), axial 
CT and axial fused images for a 35-year-old female presented with 
right breast cancer; by conventional staging, the patient was stage 
T2N1M0 (stage IIB). Fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) revealed metabolically 
active internal mammary lymph node that was indistinct in 
conventional images; the staging was upstaged to T2N3M0 (IIIC). (b) 
FDG PET/CT showing metabolically active right breast neoplasm. (c) 
PET/CT showing metabolically active right internal mammary lymph 
node (green arrow)
a
b
c
Extent of the disease
Since the same AJCC stage can be determined 
by variable combinations of T, N, and M findings, 
not all differences in one component are reflected in 
a corresponding change in the overall AJCC stage. 
Although the same T, N, and/or M status can be assigned 
in many of these patients, details of the distribution and 
 Tawakol et al. Breast Cancer Staging
Open Access Maced J Med Sci. 2020 Dec 15; 8(A):970-975. 973
extent of the disease could have a major impact on 
management decisions.
18F-FDG PET/CT revealed previously unknown 
distant nodal involvement in additional 11 patients 
(13.7%) by detecting FDG-avid lymph nodes in cervical, 
mediastinal, or abdominal nodes, all of them were not 
fitting the criteria for metastatic LNs on CE-CT.
18F-FDG PET/CT revealed previously 
undetected osseous lesions in five additional patients 
(6.2%) that were undetected by conventional imaging. 
18F-FDG PET/CT and CE-CT were positive for an 
osseous spread in 24 patients. Of them, 14 patients 
showed more osseous lesions on 18F-FDG PET/CT.
18F-FDG PET/CT revealed previously unknown 
hepatic deposits in two additional patients (2.5%) that 
were undetected by conventional imaging.
Furthermore, 18F-FDG PET/CT identified 
additional sites of distant disease in stage IV patients in 
10 patients; pleura (n = 3), adrenal (n = 1), peritoneum 
(n = 1), adnexa (n = 1), pericardium (n = 1), and soft 
tissue (n = 2); all of them were missed on CE-CT.
Figure 2: Three dimensional maximum intensity projection (a), axial 
CT and axial fused images for a 40-year-old female patient presented 
with right breast cancer; by conventional staging, the patient was 
stage T4N3M1 (Stage IV), showing multiple contralateral axillary 
and mediastinal nodes. After fluorodeoxyglucose (FDG) positron 
emission tomography/computed tomography (PET/CT), there was 
no change in staging, but FDG PET/CT reveals right pleural and 
osseous lesions that were indistinct in CT, (b) FDG PET/CT showed 
metabolically active locally advanced right breast cancer, metastatic 
axillary, and mediastinal lymph nodes, (c) FDG PET/CT showed 
metabolically active right pleural lesion (green arrow). (d) FDG PET/
CT showed a metabolically active osseous lesion in T9 vertebra 
(green arrowhead)
a
b
c
d
Impact on management
According to 18F-FDG PET/CT results, the 
radiation therapy field and/or systemic therapy was 
modified in 21 patients (26.2%). 18F-FDG PET/CT led 
to extension of radiation field in 12 patients with internal 
mammary lymph nodal metastases (Figures 1-4).
Primary treatment approach was changed from 
surgery to neoadjuvant chemotherapy (before surgery) 
Figure 3: Three dimensional maximum intensity projection (a), 
axial CT and axial fused images for a 77-year-old female patient 
presented with left breast neoplasm; by conventional staging, 
the patient was stage T1N1M0 (stage IIA). Fluorodeoxyglucose 
positron emission tomography/computed tomography (PET/
CT) revealed another focal uptake corresponding to upper outer 
quadrant nodule in the right breast (black arrow) and metabolically 
active osseous lesions seen in iliac bones, T12, L5 vertebrae, and 
left acetabulum that were indistinct in conventional images; the 
staging was upstaged to T1N1M1 (Stage IV). (b) PET/CT showed 
metabolically active bilateral breast lesions. (c) PET/CT showed 
metabolically active T12 vertebra that was indistinct in CT images 
(green arrow)
a
b
c
in five patients, from curative to palliative treatment in 
three patients, and from palliative to curative treatment 
in one patient after 18F FDG-PET/CT excluded 
distant bony lesions that were considered positive on 
conventional imaging.
Figure 4: Three dimensional maximum intensity projection (a), 
axial CT and axial fused images for a 67-year-old female patient 
presented with left breast neoplasm; by conventional staging, the 
patient was stage T4N2M1 (stage IV) known to be metastatic to 
right iliac bone and T1 vertebra. After fluorodeoxyglucose (FDG) 
positron emission tomography/computed tomography (PET/CT), 
there was no change in staging, but FDG PET/CT revealed other 
breast nodules at different quadrants and osseous lesion in L4 
vertebra that were indistinct in conventional imaging (b) showed 
metabolically active left breast neoplasm in the lower inner 
quadrant extending to the outer one and ulcerating to the overlying 
skin (c and d) showed metabolically active breast lesions in upper 
quadrants (green arrows) (e) showed a metabolically active 
osseous lesion in L4 vertebra that was indistinct in CT images 
(white arrows)
a
b
c
d
e
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ultimately a modification of planned treatment in 8% 
(8/103) of patients [13].
Similarly, in our study, 18F-FDG PET/CT 
detected additional sites of distant involvement in 10 
patient (3 patients with pleural disease, 1 patient with 
adrenal deposits, 2 patients with peritoneal deposits, 1 
patient with adnexal deposits, 1 patient with pericardial 
lesions, and 2 patients with soft tissue lesions) that 
were missed by conventional CT. 18F-FDG PET/
CT also revealed previously unknown distant extra-
axillary metastases in 11/80 cases (13.7%) that were 
undetected by conventional CT.
In breast cancer, N3 nodal involvement 
(stage IIIC) has a poor prognosis [14]. Detection of 
extra-axillary lymph nodes may also have a major 
impact on the loco-regional treatment, for example, 
by defining the target volume for radiotherapy or the 
extent of the surgical clearance. Hence, 18F-FDG 
PET/CT is a valuable tool to detect unsuspected 
extra-axillary lymph nodes and distant metastases 
[15]. According to our results, 18F-FDG PET/CT 
findings impacted treatment planning in 21 (26.2%) 
patients, of them, 12 patients had their radiation 
field extended secondary to detecting internal 
mammary LN involvement on 18F-FDG PET/CT. Our 
results are in agreement with the results of other 
series [15], [16], [17].
The limitations of this study include a 
small sample size, which reduced the power of our 
conclusions, and the absence of histopathological 
validation. Many diagnostic studies fall short when it 
comes to the use of a real gold standard, especially 
when employing a whole-body coverage biopsy would 
be a questionable method, both from logistic and 
ethical perspectives. In practice, treating physicians 
usually make complex judgments decisions based on 
the best available evidence. We still believe that our 
findings are appropriate since the main purpose of 
this study was to answer the question of “detectability” 
and establish the magnitude of “differences” between 
the methods, rather than a “diagnostic performance” 
question, where an independent diagnostic method is 
required.
Another important limitation is that our 
patients were recruited in our study after a standard 
conventional workup was performed outside our 
institution; accordingly, the methodology employed 
in data acquisition and reporting quality cannot be 
verified.
On the other hand, the advantages of this study 
included its prospective design, uniform acquisition and 
interpretation protocols for the PET and CE-CT, and 
reporting the practical impact of PET/CT reporting on 
the management of breast cancer patients with clinically 
suspected advanced local disease. We believe that our 
results can inform future hypothesis-driven prospective 
studies to study the impact of using one diagnostic tool 
versus the other.
Discussion
Breast cancer remains the most common 
type of non-skin cancer in women. Accurate staging 
is important for the management of the disease. 
In breast cancer staging, the TNM classification is 
used [10]. The National Comprehensive Cancer 
Network guidelines recommend assessment with 18F-
FDG PET/CT for staging of breast cancer, starting 
from the stage IIIA [11]. Our aim is to evaluate the 
contribution of 18F-FDG PET/CT in the staging of 
breast cancer patients and the impact of this on the 
management approaches.
In this study, impressions from 18F-FDG PET/
CT changed the AJCC stage in 30% of the patients. 
Similarly, Fuster et al. found that 18F-FDG PET/CT 
led to a change in the initial staging in 42% of their 
cohort with 60 patients, reporting that the overall 
sensitivity and specificity for 18F-FDG PET/CT were 
significantly higher to those of diagnostic CT, which 
makes this technique recommendable in the staging of 
patients with large primary breast cancer. The results 
obtained in their study suggest that 18F-FDG PET/
CT underestimates loco-regional lymph node staging 
in large primary breast cancer patients. Locally, 26 
patients (32.5%) of our cohort showed different local 
disease extent (T status) from 18F-FDG PET/CT 
compared to conventional imaging. 18F-FDG PET/CT 
detected multifocal lesions more frequently than the 
combination of mammography and ultrasonography. 
Although histopathological confirmation was not 
available, those patients were treated either with 
neoadjuvant chemotherapy or palliatively according to 
the final stage.
Gil-Rendo et al. published a prospective 
study focusing on the role of 18F-FDG PET in the 
axillary staging of 275 patients with stage I and stage 
II diseases. The authors found a change of treatment 
in overall 33% of patients when taking into account 
sparing of sentinel lymph node biopsy in cases of 
positive FDG uptake in the axilla [12]. Likewise, in the 
current study, 18F FDG-PET/CT revealed previously 
undetectable regional lymphatic spread in a total of 27 
patients (11 infraclavicular, 4 supraclavicular, and 12 
internal mammary lymph nodes).
Bernsdorf et al. did not perform abdominal 
imaging or bone scans on any patients and their 
workup included only mammography, breast and 
axillary ultrasound, chest X-ray, and blood samples. 
In their study, 18F-FDG PET/CT solely detected 
distant metastases (ovary, bones, and lung) in six 
patients and new primary cancers (ovary, lung) in 
another two patients. Furthermore, they reported 12 
patients with extra-axillary lymph nodal involvement. 
In 15 patients (15%), extra-axillary malignancy 
was detected by 18F-FDG PET/CT only, leading to 
an upgrade of initial staging in 14% (14/103) and 
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Conclusions
18F-FDG PET/CT is an efficient imaging 
modality for staging of patients with clinically suspected 
advanced breast cancer not only for detecting distant 
lesions but also for detecting axillary and extra-axillary 
nodes and multifocality/multicentricity in the primary 
tumor site.
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